TokenPost·
Halozyme Therapeutics Raises 2026 Revenue Outlook After Q3 Beat
Third-quarter revenue rose 39% year over year to $493 million, while non-GAAP earnings per share reached $2.39, 3 cents above estimates.
More news
- CryptoSlateMEXC sees $126 million outflows as US targets exchange over $16.7 billion in suspected illicit transactions
- TokenPostZiff Davis’ Operating Results Swing to Loss as Revenue Falls 5.6%
- TokenPostTokenized iShares MSCI South Korea ETF (EWY) Falls 1.22% as Price Sits Below Averages
- TokenPostJim Cramer Says AI Stock Sell-Off Differs From Dot-Com Crash
- TokenPostMichael Saylor Says Bitcoin (BTC) Fell About 5% in Nov. 5 Post
- TokenPostXponential Fitness Cuts 2026 Studio Target as Revenue Falls 21%